Drug Trial Radar · NCT05607420
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Cellectis S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
UCART20x22Biological
Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
CLLS52Biological
A monoclonal antibody that recognizes a CD52 antigen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]Time frame: From study entry through month 12
- Dose finding part: Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to Day 28 post UCART20x22 infusion
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
The University of Chicago Medical Center (UCMC)
Chicago, Illinois · Recruiting
Harvard Medical School - Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick
New Brunswick, New Jersey · Recruiting
Sarah Cannon - St. David South Austin Medical Center
Austin, Texas · Recruiting
Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu
Nantes, France · Recruiting
Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
Pierre-Bénite, Auvergne Rhone Alpe, France · Recruiting
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie
Paris, Île-de-France Region, France · Recruiting
Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi
Montpellier, Occitanie, France · Recruiting
Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)
Seville, Spain · Recruiting
Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.